Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;14(2):121-126.
doi: 10.2174/1570163814666170117120005.

Pimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the Basics of Drug Reprofiling

Suzanne J Dilly  1 , George S Morris  2
Affiliations
Review

Pimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the Basics of Drug Reprofiling

Suzanne J Dilly et al. Curr Drug Discov Technol. 2017.

Abstract

Drug development has moved along way forward from the days of with doctors peddling cauldrons of herbs and spices, however, the process can still miss opportunities for full exploitation of a drug's potential. Drug reprofiling provides a chance for an established or a forgotten drug to move into a new area of therapy, whether related to the known effects or in a completely new area. In an era of environmental awareness and spiraling costs for traditional drug development, a strategy to squeeze every benefit out of drugs with known safety, tolerability and pharmacological parameters must be a strategically sound desire. We explore examples of success in reprofiling, draw comparisons between techniques, and finally provide two examples from the Valirx plc development pipeline currently undergoing the process.

Keywords: Reprofiling; cancer; development; health economics; risperidone; techniques.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

References

    1. Wigglesworth M.J., Murray D.C., Blackett C.J., Kossenjans M., Nissink J.M. Increasing the delivery of next generation therapeutics from high throughput screening libraries. Curr. Opin. Chem. Biol. 2015;26:104–110. - PubMed
    1. Banerjia U., Workman P. Critical parameters in targeted drug development: The pharmacological audit trail. Semin. Oncol. 2016;43(4):436–445. - PubMed
    1. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012;75(3):311–335. - PMC - PubMed
    1. Avorn J. The $2.6 billion pill-methodologic and policy considerations. N. Engl. J. Med. 2015;372:1877–1879. - PubMed
    1. Waring M.J., Arrowsmith J., Leach A.R., et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 2015;14:475–486. - PubMed